Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initial Vancomycin Taper for the Prevention of Recurrent Clostridioides Difficile Infection 2
NCT07328971Phase 3Recruiting
- Sponsor
- McGill University Health Centre
- Start
- Apr 2026
- Primary completion
- Jun 2030
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vancomycin in Clostridioides difficile infection (CDI), sponsored by McGill University Health Centre. Started Apr 2026; status: recruiting.
02
Drugs
vancomycin
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT07328971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07328971.